Skip to main content
Premium Trial:

Request an Annual Quote

Signal Genetics Signs Reimbursement Agreement with America's Choice Provider Network

NEW YORK (GenomeWeb) – Signal Genetics today announced that is has signed an agreement to make its MyPRS assay available to 22 million patients covered by America's Choice Provider Network (ACPN).

MyPRS is microarray-based prognostic test for multiple myeloma and stratifies patients into molecular subtypes and into high- and low-risk categories using gene expression profiling.

"[W]e expect increased reimbursement support for our assay through agreements such as this to have a positive impact on our revenue generation over the long term," Signal Genetics CFO Tamara Seymour said in a statement. "As part of our overall growth strategy, we will continue to seek out these types of opportunities to ensure stable reimbursement as we work to make MyPRS available for physicians and patients across the US."

In April, Carlsbad, California-based Signal Genetics received accreditation from the College of American Pathologists for its laboratory in Little Rock, Arkansas.

The Scan

Suicidal Ideation-Linked Loci Identified Using Million Veteran Program Data

Researchers in PLOS Genetics identify risk variants within and across ancestry groups with a genome-wide association study involving veterans with or without a history of suicidal ideation.

Algorithm Teases Out Genetic Ancestry in Individuals at Biobank Scale

Researchers develop an algorithm known as Rye to tease apart ancestry fractions in admixed individuals at a biobank-scale, applying it to 488,221 UK Biobank participants in Nucleic Acids Research.

Multi-Ancestry Analysis Highlights Comparable Common Variants at Complex Trait-Linked Loci

Researchers in Nature Genetics examine common variants implicated in more than three dozen conditions, estimating genetic effect similarities across ancestry tracts in admixed individuals.

Sick Newborns Selected for WGS With Automated Pipeline

Researchers successfully prioritized infants with potential Mendelian conditions for whole-genome sequencing or rapid whole-genome sequencing, as they report in Genome Medicine.